|
1
|
Weng CC, Ding PY, Liu YH, Hawse JR,
Subramaniam M, Wu CC, Lin YC, Chen CY, Hung WC and Cheng KH: Mutant
Kras induced upregulation of CD24 enhances prostate cancer stemness
and bone metastasis. Oncogene. 38:2005–2019. 2019. View Article : Google Scholar
|
|
2
|
Rawla P: Epidemiology of prostate cancer.
World J Oncol. 10:63–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fong LY, Jing R, Smalley KJ, Wang ZX,
Taccioli C, Fan S, Chen H, Alder H, Huebner K, Farber JL, et al:
Human like hyper plastic prostate with low ZIP1 induced solely by
Zn deficiency in rats. Proc Natl Acad Sci USA. 115:E11091–E11100.
2018. View Article : Google Scholar
|
|
4
|
Barry MJ and Simmons LH: Prevention of
prostate cancer morbidity and mortality: Primary prevention and
early detection. Med Clin North Am. 101:787–806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Daniyal M, Siddiqui ZA, Akram M, Asif HM,
Sultana S and Khan A: Epidemiology, etiology, diagnosis and
treatment of prostate cancer. Asian Pac J Cancer Prev.
15:9575–9578. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cuzick J, Thorat MA, Andriole G, Brawley
OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et
al: Prevention and early detection of prostate cancer. Lancet
Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pezaro C, Woo HH and Davis ID: Prostate
cancer: Measuring PSA. Intern Med J. 44:433–440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohamad NV, Soelaiman IN and Chin KY: A
review on the effects of androgen deprivation therapy (ADT) on bone
health status in men with prostate cancer. Endocr Metab Immune
Disord Drug Targets. 17:276–284. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munkley J, Vodak D, Livermore KE, James K,
Wilson BT, Knight B, Mccullagh P, Mcgrath J, Crundwell M, Harries
LW, et al: Glycosylation is an androgen regulated process essential
for prostate cancer cell viability. EBioMedicine. 8:103–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reina Campos M, Linares JF, Duran A,
Cordes T, L'Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards
A, Rooslid T, et al: Increased serine and one carbon pathway
metabolism by PKClambda/iota deficiency promotes neuroendo crine
prostate cancer. Cancer Cell. 35:385–400.e9. 2019. View Article : Google Scholar
|
|
11
|
Xu K, Ganapathy K, Andl T, Wang Z, Copland
JA, Chakrabarti R and Florczyk SJ: 3D porous chitosan-alginate
scaffold stiffness promotes differential responses in prostate
cancer cell lines. Biomaterials. 217:1193112019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai J, Sultan S, Taylor SS and Higgins JM:
The kinase haspin is required for mitotic histone H3 Thr 3
phosphorylation and normal metaphase chromosome alignment. Genes
Dev. 19:472–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kestav K, Uri A and Lavogina D: Structure,
Roles and inhibi tors of a mitotic protein kinase haspin. Curr Med
Chem. 24:2276–2293. 2017. View Article : Google Scholar
|
|
14
|
Opoku Temeng C, Dayal N, Aflaki
Sooreshjani M and Sintim HO: 3H-pyrazolo[4,3-f]quinoline haspin
kinase inhibi tors and anticancer properties. Bioorg Chem.
78:418–426. 2018. View Article : Google Scholar
|
|
15
|
Lavogina D, Kestav K, Chaikuad A, Heroven
C, Knapp S and Uri A: Co crystal structures of the protein kinase
haspin with bisubstrate inhibitors. Acta Crystallogr F Struct Biol
Commun. 72:339–345. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JE, Lee SY, Jang M, Choi HK, Kim JH,
Chen H, Lim TG, Dong Z and Lee KW: Coumestrol epigenetically
suppresses cancer cell proliferation: Coumestrol is a natural
haspin kinase inhibitor. Int J Mol Sci. 18:pii: E2228. 2017.
View Article : Google Scholar
|
|
17
|
Amoussou NG, Bigot A, Roussakis C and
Robert JH: Haspin: A promising target for the design of inhibitors
as potent anticancer drugs. Drug Discov Today. 23:409–415. 2018.
View Article : Google Scholar
|
|
18
|
Han L, Wang P, Sun Y, Liu S and Dai J:
Anti melanoma activi ties of haspin inhibitor CHR 6494 deployed as
a single agent or in a synergistic combination with MEK inhibitor.
J Cancer. 8:2933–2943. 2017. View Article : Google Scholar :
|
|
19
|
Scheff NN, Alemu RG, Klares R III, Wall
IM, Yang SC, Dolan JC and Schmidt BL: Granulocyte colony
stimulating factor induced neutrophil recruitment provides opioid
mediated endogenous anti-nociception in female mice with oral
squamous cell carci noma. Front Mol Neurosci. 12:2172019.
View Article : Google Scholar
|
|
20
|
Pfaffl MW: Pfaffl A new mathematical model
for relative quan tification in real-time RT-PCR. Nucleic Acids
Res. 29:e452001. View Article : Google Scholar
|
|
21
|
Metzger E, Wang S, Urban S, Willmann D,
Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, et al:
KMT9 monomethylates histone H4 lysine 12 and controls proliferation
of prostate cancer cells. Nat Struct Mol Biol. 26:361–371. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fong KW, Zhao JC, Song B, Zheng B and Yu
J: TRIM28 protects TRIM24 from SPOP mediated degradation and
promotes pros tate cancer progression. Nat Commun. 9:50072018.
View Article : Google Scholar
|
|
23
|
Canesin G, Evans Axelsson S, Hellsten R,
Sterner O, Krzyzanowska A, Andersson T and Bjartell A: The STAT3
inhibitor galiellalactone effectively reduces tumor growth and
metastatic spread in an orthotopic xenograft mouse model of
prostate cancer. Eur Urol. 69:400–404. 2016. View Article : Google Scholar
|
|
24
|
Wang Z, Wang Y, Zhu S, Liu Y, Peng X,
Zhang S, Zhang Z, Qiu Y, Jin M, Wang R, et al: DT 13 inhibits
proliferation and metastasis of human prostate cancer cells through
blocking PI3K/Akt pathway. Front Pharmacol. 9:14502018. View Article : Google Scholar
|
|
25
|
Maiolica A, de Medina Redondo M, Schoof
EM, Chaikuad A, Villa F, Gatti M, Jeganathan S, Lou HJ, Novy K,
Hauri S, et al: Modulation of the chromatin phosphoproteome by the
Haspin protein kinase. Mol Cell Proteomics. 13:1724–1740. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patnaik D, Jun X, Glicksman MA, Cuny GD,
Stein RL and Higgins JM: Identification of small molecule
inhibitors of the mitotic kinase haspin by high throughput
screening using a homogeneous time resolved fluorescence resonance
energy transfer assay. J Biomol Screen. 13:1025–1034. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Balzano D, Santaguida S, Musacchio A and
Villa F: A general framework for inhibitor resistance in protein
kinases. Chem Biol. 18:966–975. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang F, Ulyanova NP, Daum JR, Patnaik D,
Kateneva AV, Gorbsky GJ and Higgins JM: Haspin inhibitors reveal
centro meric functions of Aurora B in chromosome segregation. J
Cell Biol. 199:251–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, He
P, Kang Z, Yin L, Zhao Y, et al: Ligand dependent EphA7 signaling
inhibits pros tate tumor growth and progression. Cell Death Dis.
8:e31222017. View Article : Google Scholar
|
|
30
|
Zabala Letona A, Arruabarrena Aristorena
A, Martín Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M,
Tomas-Cortazar J, Jimenez J, Torres I, Quang P, et al: mTORC1
dependent AMD1 regulation sustains polyamine metabolism in prostate
cancer. Nature. 547:109–113. 2017. View Article : Google Scholar
|
|
31
|
Jing X, Sonoki T, Miyajima M, Sawada T,
Terada N, Takemura S and Sakaguchi K: EphA4 deleted
microenvironment regulates cancer development and leukemoid
reaction of the isografted 4T1 murine breast cancer via reduction
of an IGF1 signal. Cancer Med. 5:1214–1227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z,
Wu Z, Wang H, Xu X, Zhang H, et al: Downregulation of EphA5 by
promoter methylation in human prostate cancer. BMC Cancer.
15:182015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li S, Ma Y, Xie C, Wu Z, Kang Z, Fang Z,
Su B and Guan M: EphA6 promotes angiogenesis and prostate cancer
metastasis and is associated with human prostate cancer
progression. Oncotarget. 6:22587–22597. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ivanova IA, Vermeulen JF, Ercan C,
Houthuijzen JM, Saig FA, Vlug EJ, van der Wall E, van Diest PJ,
Vooijs M and Derksen PW: FER kinase promotes breast cancer
metastasis by regulating α6 and β1 integrin dependent cell adhesion
and anoikis resistance. Oncogene. 32:5582–5592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vishwamitra D, George SK, Shi P, Kaseb AO
and Amin HM: Type I insulin like growth factor receptor signaling
in hemato logical malignancies. Oncotarget. 8:1814–1844. 2017.
View Article : Google Scholar
|
|
36
|
Jay J, Hammer A, Nestor Kalinoski A and
Diakonova M: JAK2 tyrosine kinase phosphorylates and is negatively
regulated by centrosomal protein Ninein. Mol Cell Biol. 35:111–131.
2015. View Article : Google Scholar :
|
|
37
|
Roll JD and Reuther GW: ALK activating
homologous mutations in LTK induce cellular transformation. PLoS
One. 7:e317332012. View Article : Google Scholar
|
|
38
|
Prchal-Murphy M, Witalisz-Siepracka A,
Bednarik KT, Putz EM, Gotthardt D, Meissl K, Sexl V, Müller M and
Strobl B: In vivo tumor surveillance by NK cells requires TYK2 but
not TYK2 kinase activity. Oncoimmunology. 4:e10475792015.
View Article : Google Scholar :
|
